Central Lab Market - Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Genetic Disorders Owing to Rising Mutations -A genetic disorder is a medical disease caused by one or more malformations in the genome. These disorders consist of several types of chronic diseases and birth defects that are received from one or both parents. Such disorders require in-depth research and study to discover an optimum treatment. For instance, there are over 6,010 clinically defined rare diseases, out of these 72% are genetic disorders.
- Rise in Genetic Testing as the Number of Genetic Cases Increasing - Changes in genes, chromosomes, or proteins are detected through genetic testing. Genetic test results confirm or rule out a suspected genetic condition. The increasing number of genetic abnormalities is leading to the growth of genetic testing. For instance, by 2021, over 78,000 genetic tests were in use.
- Increasing Prevalence of Cancer in All Age Groups of Population - Cancer is one of the leading causes of death globally and numerous clinical trials have been performed to find out the best-suited treatment for it. As per the data provided by the World Health Organization (WHO), nearly 10 million people died from cancer worldwide in 2020.
- Upsurge in Cardiovascular Diseases (CVDs) Across the World - Conditions affecting the heart or blood vessels are collectively referred to as cardiovascular disease (CVD). It is commonly related to a buildup of fatty deposits inside the arteries. The number of CVDs patients is growing faster which leads to the rising number of testing and trials for new and effective drugs. As per the World Health Organization, in 2019, approximately 17.9 million people died from CVDs, representing 32% of all deaths worldwide.
- Growing Investment in R&D with Government and Private Support – According to the data released by the Unesco Institute for Statistics, worldwide R&D investment has continued to rise, with an average annual increase of 4.7% over the last decade (2010-2020). In global terms, the proportion of global GDP invested in R&D has grown substantially from 1.61% in 2010 to 1.93% in 2020.
Challenges
- Requirement of High Capital Investments to Operate Central Lab
- The need for high capital investment to develop and operate a central lab is estimated to hamper the market growth. The central lab requires costly equipment, skilled medical professionals to handle the equipment, and a large space to set up a sophisticated lab facility.
- Problems Associated with Contamination of Samples
- Stringent Government Regulations
Central Lab Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
5.7% |
|
Base Year Market Size (2025) |
USD 3.62 billion |
|
Forecast Year Market Size (2035) |
USD 6.3 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of central lab is evaluated at USD 3.81 billion.
The global central lab market size exceeded USD 3.62 billion in 2025 and is set to expand at a CAGR of over 5.7%, surpassing USD 6.3 billion revenue by 2035.
North America’s central lab market will dominate over 40.6% share by 2035, driven by increased R&D spending and rising prevalence of chronic diseases.
Key players in the market include Laboratory Corporation of America Holdings (Labcorp), ICON Plc, Medpace, Inc., Eurofins Scientific (Ireland) Limited, LabConnect, Cerba Research NV, Frontage Laboratories, Inc., Lambda Therapeutic Research Limited, InVitro International (IVRO), Clinical Reference Laboratory, Inc.